Business Description
Puma Biotechnology Inc
NAICS : 325412
SIC : 2834
ISIN : US74587V1070
Total Employee Number:
179Description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.37 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 0.36 | |||||
Interest Coverage | 5.7 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | -3.15 | |||||
Beneish M-Score | -3.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.9 | |||||
3-Year EBITDA Growth Rate | 29.3 | |||||
3-Year EPS without NRI Growth Rate | 42.4 | |||||
3-Year Book Growth Rate | 77 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -40.84 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -1.79 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.2 | |||||
9-Day RSI | 66.61 | |||||
14-Day RSI | 64.66 | |||||
3-1 Month Momentum % | 2.03 | |||||
6-1 Month Momentum % | 19.97 | |||||
12-1 Month Momentum % | 96.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.38 | |||||
Quick Ratio | 2.24 | |||||
Cash Ratio | 1.7 | |||||
Days Inventory | 51.61 | |||||
Days Sales Outstanding | 52.9 | |||||
Days Payable | 39.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.8 | |||||
Shareholder Yield % | 11.06 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.46 | |||||
Operating Margin % | 12.98 | |||||
Net Margin % | 10.73 | |||||
EBITDA Margin % | 19.8 | |||||
FCF Margin % | 23.59 | |||||
OCF Margin % | 23.6 | |||||
ROE % | 21.17 | |||||
ROA % | 12.16 | |||||
ROIC % | 24.35 | |||||
3-Year ROIIC % | -285.81 | |||||
ROC (Joel Greenblatt) % | 447.84 | |||||
ROCE % | 27.93 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 17.13 | |||||
Forward PE Ratio | 28.34 | |||||
PE Ratio without NRI | 13.48 | |||||
Price-to-Owner-Earnings | 11.09 | |||||
PS Ratio | 1.83 | |||||
PB Ratio | 3.26 | |||||
Price-to-Tangible-Book | 4.68 | |||||
Price-to-Free-Cash-Flow | 7.78 | |||||
Price-to-Operating-Cash-Flow | 7.78 | |||||
EV-to-EBIT | 9.71 | |||||
EV-to-EBITDA | 7.4 | |||||
EV-to-Revenue | 1.46 | |||||
EV-to-Forward-Revenue | 0.64 | |||||
EV-to-FCF | 6.21 | |||||
Price-to-GF-Value | 2.46 | |||||
Price-to-Projected-FCF | 1.5 | |||||
Price-to-Graham-Number | 1.68 | |||||
| Price-to-Net-Current-Asset-Value | 5.38 | |||||
| Price-to-Net-Cash | 11.27 | |||||
Earnings Yield (Greenblatt) % | 10.3 | |||||
FCF Yield % | 12.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PBYI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Puma Biotechnology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 227.178 | ||
| EPS (TTM) ($) | 0.48 | ||
| Beta | 1.8197 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 1.28 | ||
| Volatility % | 67.96 | ||
| 14-Day RSI | 64.66 | ||
| 14-Day ATR ($) | 0.323929 | ||
| 20-Day SMA ($) | 7.5875 | ||
| 12-1 Month Momentum % | 96.37 | ||
| 52-Week Range ($) | 3.03 - 8.44 | ||
| Shares Outstanding (Mil) | 50.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Puma Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Puma Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 31 days | ||
| General meeting for 2026 | 2026-06-11 13:00 | 7.02 (-0.71%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 7.45 (+0.13%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 7.45 (+0.13%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 14:30 | 5.70 (-9.52%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 16:30 | 7.68 (+2.26%) | ||
| Annual report for 2025 | 2026-02-26 | 7.68 (+2.26%) |
Show
Entries
Puma Biotechnology Inc Frequently Asked Questions
What is Puma Biotechnology Inc(PBYI)'s stock price today?
The current price of PBYI is $8.23. The 52 week high of PBYI is $8.44 and 52 week low is $3.03.
When is next earnings date of Puma Biotechnology Inc(PBYI)?
The next earnings date of Puma Biotechnology Inc(PBYI) is 2026-08-07 Est..
Does Puma Biotechnology Inc(PBYI) pay dividends? If so, how much?
Puma Biotechnology Inc(PBYI) does not pay dividend.
Guru Commentaries on NAS:PBYI
No articles.
Press Release
Articles on Puma Biotechnology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers